Structure-guided discovery of cyclin-dependent kinase inhibitors

被引:53
作者
Fischmann, Thierry O. [1 ]
Hruza, Alan [1 ]
Duca, Jose S. [1 ]
Ramanathan, Lata [1 ]
Mayhood, Todd [1 ]
Windsor, William T. [1 ]
Le, Hung V. [1 ]
Guzi, Thimothy J. [1 ]
Dwyer, Michael P. [1 ]
Paruch, Kamil [1 ]
Doll, Ronald J. [1 ]
Lees, Emma [2 ]
Parry, David [2 ]
Seghezzi, Wolfgang [2 ]
Madison, Vincent [1 ]
机构
[1] Schering Plough Res Inst, Kenilworth, NJ 07033 USA
[2] Schering Plough Biopharma, Palo Alto, CA 94034 USA
关键词
crystal structures; CDK2; inhibitors; interaction energies;
D O I
10.1002/bip.20868
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 [生物化学与分子生物学]; 081704 [应用化学];
摘要
CDK2 inhibitors containing the related bicyclic heterocycles pyrazolopyrimidines and imidazopyrazines were discovered through high-throughput screening. Crystal structures of inhibitors with these bicyclic cores and two more related ones show that all but one have a common binding mode featuring two hydrogen bonds (H-bonds) to the backbone of the kinase hinge region. Even though ab initio computations indicated that the imidazopyrazine core would bind more tightly to the hinge, pyrazolopyrimidines gain an advantage in potency through participation of N4 in an H-bond network involving two catalytic residues and bridging water molecules. Further insight into inhibitor/CDK2 interactions was gained from analysis of additional crystal structures. Significant gains in potency were obtained by optimizing the fit of hydrophobic substituents to the gatekeeper region of the ATP binding site. The most potent inhibitors have good selectivity. (c) 2007 Wiley Periodicals, Inc.
引用
收藏
页码:372 / 379
页数:8
相关论文
共 35 条
[1]
Identification of novel purine and pyrimidine cyclin-dependent kinase inhibitors with distinct molecular interactions and tumor cell growth inhibition profiles [J].
Arris, CE ;
Boyle, FT ;
Calvert, AH ;
Curtin, NJ ;
Endicott, JA ;
Garman, EF ;
Gibson, AE ;
Golding, BT ;
Grant, S ;
Griffin, RJ ;
Jewsbury, P ;
Johnson, LN ;
Lawrie, AM ;
Newell, DR ;
Noble, MEM ;
Sausville, EA ;
Schultz, R ;
Yu, W .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (15) :2797-2804
[2]
The Protein Data Bank [J].
Berman, HM ;
Westbrook, J ;
Feng, Z ;
Gilliland, G ;
Bhat, TN ;
Weissig, H ;
Shindyalov, IN ;
Bourne, PE .
NUCLEIC ACIDS RESEARCH, 2000, 28 (01) :235-242
[3]
Phase 1 trial of flavopiridol combined with cisplatin or carboplatin in patients with advanced malignancies with the assessment of pharmacokinetic and pharmacodynamic end points [J].
Bible, KC ;
Lensing, JL ;
Nelson, SA ;
Lee, YK ;
Reid, JM ;
Ames, MM ;
Isham, CR ;
Piens, J ;
Rubin, SL ;
Rubin, J ;
Kaufmann, SH ;
Atherton, PJ ;
Sloan, JA ;
Daiss, MK ;
Adjei, AA ;
Erlichman, C .
CLINICAL CANCER RESEARCH, 2005, 11 (16) :5935-5941
[4]
CALCULATION OF SMALL MOLECULAR INTERACTIONS BY DIFFERENCES OF SEPARATE TOTAL ENERGIES - SOME PROCEDURES WITH REDUCED ERRORS [J].
BOYS, SF ;
BERNARDI, F .
MOLECULAR PHYSICS, 1970, 19 (04) :553-&
[5]
Bayesian statistical viewpoint on structure determination: Basic concepts and examples [J].
Bricogne, G .
MACROMOLECULAR CRYSTALLOGRAPHY, PT A, 1997, 276 :361-423
[6]
Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine [J].
DeAzevedo, WF ;
Leclerc, S ;
Meijer, L ;
Havlicek, L ;
Strnad, M ;
Kim, SH .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2) :518-526
[7]
Delano W. L, PYMOL MOL GRAPHICS S
[8]
Insights from ab initio quantum chemical calculations into the preferred tautomeric forms and binding affinities to CDK2 of substituted pyrazolopyridines [J].
Duca, JS ;
Madison, VS .
BIOPOLYMERS, 2005, 80 (2-3) :312-318
[10]
Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors [J].
Dwyer, Michael P. ;
Paruch, Kamil ;
Alvarez, Carmen ;
Doll, Ronald J. ;
Keertikar, Kerry ;
Duca, Jose ;
Fischmann, Thierry O. ;
Hruza, Alan ;
Madison, Vincent ;
Lees, Emma ;
Parry, David ;
Seghezzi, Wolfgang ;
Sgambellone, Nicole ;
Shanahan, Frances ;
Wiswell, Derek ;
Guzi, Timothy J. .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2007, 17 (22) :6216-6219